BioWorld Asia

Jan. 26, 2005

OctoPlus Raises EUR18.25M For Drug Development, Delivery

OctoPlus BV raised €18.25 million (US$23.6 million) in a second funding round that will enable it to progress its drug development and delivery programs and to widen its product pipeline. (BioWorld International) Read More

CeNeS Gets Positive Phase III Data For M6G, Plans Another

Immune Cells Reprogrammed As Cancer Killers, Study Shows

Stroke Company Paion AG Testing German IPO Waters

Crucell Mulls Funding Moves For Clinical Studies In 2005

UroGene Sells Research Center, Cancer Programs to Pierre Fabre

With More Phase III Data, GW Hoping For IND Filing In U.S.

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...